Aquestive Therapeutics (AQST)
(Real Time Quote from BATS)
$2.62 USD
-0.13 (-4.73%)
Updated Jun 10, 2024 10:02 AM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AQST 2.62 -0.13(-4.73%)
Will AQST be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
5 Small Drug Stocks to Buy From a Recovering Industry
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for AQST
Aquestive Therapeutics Shares Investor Presentation Update
Aquestive Therapeutics Appoints Cassie Jung as COO
Aquestive Therapeutics Poised for Growth with Anaphylmâ„¢ and Strategic Executive Additions: A Buy Rating Justified
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Aquestive Therapeutics appoints Cassie Jung as COO, Stephen Wargacki as CSO